Articles dans des revues avec comité de lecture (396)
  1. 181. Awada, A., Bozovic, I., & Chow, L. (2012). New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer treatment reviews, 38(5), 494-504. doi:10.1016/j.ctrv.2012.01.001
  2. 182. Bergh, J., Mariani, G., Cardoso, F., Liljegren, A., Awada, A., Vigano, L., Huang, X., Verkh, L., Kern, K. A., Giorgetti, C., & Gianni, L. (2012). Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast, 21(4), 507-513. doi:10.1016/j.breast.2012.01.012
  3. 183. Schuler, M., Awada, A., Harter, P., Canon, J.-L., Possinger, K., Schmidt, M., De Greve, J., Neven, P., Dirix, L. Y., Jonat, W., Beckmann, M. W., Schütte, J., Fasching, P. A., Gottschalk, N., Besse-Hammer, T., Fleischer, F., Wind, S., Uttenreuther-Fischer, M., Piccart-Gebhart, M., & Harbeck, N. (2012). A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast cancer research and treatment, 134(3), 1149-1159. doi:10.1007/s10549-012-2126-1
  4. 184. Hendlisz, A., Golfinopoulos, V., Garcia, C., Covas, A., Emonts, P., Ameye, L., Paesmans, M., Deleporte, A., Machiels, G., Toussaint, E., Vanderlinden, B., Awada, A., Piccart-Gebhart, M., & Flamen, P. (2012). Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Annals of oncology, 23(7), 1687-1693. doi:10.1093/annonc/mdr554
  5. 185. Awada, A., Vandone, A. M., & Aftimos, P. (2012). Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Current opinion in oncology, 24(3), 297-304. doi:10.1097/CCO.0b013e3283521349
  6. 186. Abdel Azim, H. H., & Awada, A. (2012). Clinical development of new formulations of cytotoxics in solid tumors. Current opinion in oncology, 24(3), 325-331. doi:10.1097/CCO.0b013e328351fb29
  7. 187. de Castro, G., & Awada, A. (2012). Second primary cancers in head and neck cancer patients: a challenging entity. Current opinion in oncology, 24(3), 203-204. doi:10.1097/CCO.0b013e3283519183
  8. 188. Awada, A., Hendlisz, A., Christensen, O., Lathia, C., Bartholomeus, S., Lebrun, F., de Valeriola, D., Brendel, E., Radtke, M., Delaunoit, T., Piccart-Gebhart, M., & Gil, T. (2012). Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. European journal of cancer, 48(4), 465-474. doi:10.1016/j.ejca.2011.12.026
  9. 189. Berghmans, T., Remmelink, M., & Awada, A. (2012). Anaplastic lymphoma kinase (ALK) inhibitors for second line therapy of Non-Small Cell Lung Cancer. Lung cancer (Auckland), 3, 91-99.
  10. 190. Klastersky, J., & Awada, A. (2012). Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Critical reviews in oncology/hematology, 81(1), 49-57. doi:10.1016/j.critrevonc.2011.02.002
  11. 191. Schöffski, P., Awada, A., Dumez, H., Gil, T., Bartholomeus, S., Wolter, P., Taton, M., Fritsch, H., Glomb, P., & Munzert, G. (2012). A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. European journal of cancer, 48(2), 179-186. doi:10.1016/j.ejca.2011.11.001
  12. 192. de Castro, G., Henrique dos Anjos, C., Lalami, Y., & Awada, A. (2012). Clinical trial design in head and neck cancer: From past experiences to future perspectives. Clinical investigation, 2(5), 473-481.
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>